ICICI Prudential Pharma Healthcare and Diagnostics (p.h.d) Fund Direct Plan Growth-Insured vs Nippon India Pharma Fund Direct Plan Bonus Plan Bonus
NAV, returns and costs — not a recommendation.
 ICICI Prudential Pharma Healthcare and Diagnostics (p.h.d) Fund Direct Plan Growth-Insured |  Nippon India Pharma Fund Direct Plan Bonus Plan Bonus | |
|---|---|---|
| NAV | ₹46.95 | ₹643.3432 |
| NAV date | 2026-08-19 | 2026-08-18 |
| 1 year | +7.93% | +10.50% |
| 3 year (p.a.) | +22.86% | +19.01% |
| 5 year (p.a.) | +16.84% | +14.56% |
| Expense ratio | 0.87% | 0.79% |
| Fund size | ₹6,624.58 Cr | ₹8635.75 Cr |
| Risk | Very high | — |
| Category | Sectoral Pharma and Healthcare | Sectoral Pharma and Healthcare |
Past performance does not guarantee future returns. Mutual fund investments are subject to market risks.